Characterization of O26 Enteropathogenic E. coli and Its Impli-Cation for Vaccine Development
Authors:
- Thiago Jordão da Silva LemosThiago Jordão da Silva Lemos
- Herbert Guimarães de Sousa SilvaHSHerbert Guimarães de Sousa Silva
- José Osvaldo PreviatoJPJosé Osvaldo Previato
- Lucia Mendonça-PreviatoLMLucia Mendonça-Previato
- Elisangela Oliveira de FreitaEFElisangela Oliveira de Freita
- Angela Silva BarbosaABAngela Silva Barbosa
- Marcia Regina FranzolinMFMarcia Regina Franzolin
- Luis Fernando dos SantosLSLuis Fernando dos Santos
- Bruna de Sousa MeloBMBruna de Sousa Melo
- Geovana Ferreira dos AnjosGAGeovana Ferreira dos Anjos
- Renata Hiromi Nakagima GonçalvesRGRenata Hiromi Nakagima Gonçalves
- Marta de Oliveira DomingosMDMarta de Oliveira Domingos
Preprint
- 19 December 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
O26 enteropathogenic Escherichia coli (EPEC), possesses a unique pseudocapsule composed of polysaccharides identical to the O antigen in their lipopolysaccharide (LPS) membrane. Therefore, the impact of O26 polysaccharides on the immune evasion mechanisms of capsulated O26 EPEC was investigated. Our findings reveal that the concentration of GlcNAc, an immunodominant unit of O26 polysaccharides capable of activating the MBL (Mannose Biding Lecting) pathway of the complement system, was found to be lower in capsulated EPEC O26 compared to naked shiga toxin-producing E. coli (STEC) O26 strain. It was noted that, unlike the naked STEC strain, the capsulated EPEC O26 strain was protected against lysis by the alternative pathway of the com-plement system by inhibiting C3b adhesion to its bacterial surface. Capsulated EPEC O26 strains were also able to avoid phagocytosis by macrophages. However, the immune evasion provided by the capsule was overcome in the presence of anti-O26 polysaccharide antibodies. Additionally, these antibodies were able to recognize O26 EPEC in the presence of biofilm and inhibit their adhesion to human epithelial cells. Overall, the results indicate that the O26 polysaccharides can generate an effective humoral immune response, making them promising antigens for the de-velopment of a vaccine against capsulated O26 E. coliKeywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Outbreak of hemolytic uremic syndrome with unusually severe clinical presentation caused by Shiga toxin-producing Escherichia coli O26:H11 in FranceArchives de Pédiatrie, 2022
- The role of IgG Fc receptors in antibody-dependent enhancementNature Reviews Immunology, 2020
- The Classical Lancefield Antigen of Group A Streptococcus Is a Virulence Determinant with Implications for Vaccine DesignCell Host & Microbe, 2014
- DEVELOPMENT OF A SPOT‐TITER CULTURE ASSAY FOR QUANTIFYING BACTERIA AND VIRAL INDICATORSJournal of Rapid Methods and Automation in Microbiology, 2009
- Presence of virulence and fitness gene modules of enterohemorrhagic Escherichia coli in atypical enteropathogenic Escherichia coli O26Microbes and Infection, 2007
- Rapid and cost-effective method for micro-organism enumeration based on miniaturization of the conventional plate-counting techniqueLe Lait, 2006
- Molecular analysis of a novel family of complex glycoinositolphosphoryl ceramides from Cryptococcus neoformans: structural differences between encapsulated and acapsular yeast formsGlycobiology, 2002
- Roles for Fis and YafK in biofilm formation by enteroaggregative Escherichia coliMolecular Microbiology, 2001
- The type and yield of lipopolysaccharide from symbiotically deficient Rhizobium lipopolysaccharide mutants vary depending on the extraction methodGlycobiology, 2000
- Structural studies of the Escherichia coli O26 O-antigen polysaccharideCarbohydrate Research, 1996